Clinical Trials Logo

Recurrent Gliosarcoma clinical trials

View clinical trials related to Recurrent Gliosarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05465954 Recruiting - Clinical trials for Recurrent Gliosarcoma

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Start date: January 20, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

NCT ID: NCT05139056 Recruiting - Clinical trials for Recurrent Glioblastoma

Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effect of multiple doses of NSC-CRAd-S-pk7 in treating patients with high-grade gliomas that have come back (recurrent). NSC-CRAd-S-pk7 consists of neural stem cells that carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

NCT ID: NCT05039281 Recruiting - Clinical trials for Recurrent Glioblastoma

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Start date: September 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.

NCT ID: NCT04991870 Recruiting - Clinical trials for Recurrent Gliosarcoma

Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.

NCT ID: NCT04477200 Recruiting - Clinical trials for Recurrent Glioblastoma

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

NCT ID: NCT03896568 Recruiting - Clinical trials for Recurrent Glioblastoma

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Start date: February 12, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.